QP. SHARES MAGAZINE BUY26 Feb 2015 07:14
BUY RECOMMENDATION IN TODAYS SHARE MAGAZINE. Article below
Niche drugmaker and supplier Quantum
Pharma (QP.:AIM) is set to double its
pre-tax profits this year on the back of
new product launches and contract wins.
The £139.3 million cap specialises in making
and supplying unlicensed drugs, which are not
licensed in the country they are being prescribed
or are used to treat an illness different to that
stated in its licence. These products, which are
typically difficult to source from mainstream
wholesalers, are usually supplied to hospitals and
pharmacies. They are typically used in areas such
as in paediatrics, psychiatry and palliative care.
Quantum’s shares rallied after a pre-close
update (9 Feb) confirmed that pre-tax profits in
the year to 31 January 2015 will ‘comfortably’
beat expectations. Analysts at broker Zeus
Capital forecast a £6.5 million pre-tax profit,
reversing the £2.6 million loss it made in the
previous financial year. Zeus Capital forecasts the
company will post a £12.7 million pre-tax profit in
the financial period ending 31 January 2016.
Quantum has sent six treatments to the
regulator for approval and Zeus expects the
company, through its niche pharmaceutical
products developer Colonis Pharma, to launch
at least 10 new treatments this year. Quantum
is also looking to sign new supply agreements to
pharmacies and care home operators.
Many of the company’s patients are elderly,
a growing demographic in the UK. It supplies
some 22,000 products and alongside Colonis its
other subsidiaries are UL Medicines, Biodose and
Quantum Aseptics.
raPId PrOGreSS
Quantum, which joined AIM in December 2014,
is targeting supply agreements similar to the
one it signed before Christmas when it agreed a
three-year deal to exclusively supply unlicensed
medicines to Bestway’s 774 outlets, which trade
under the Co-operative Pharmacy name.
Colonis launched its first licenced product,
Vitamin D deficiency treatment Aviticol, also in
December 2014. Current annual UK sales of the
unlicensed versions of this product are estimated
to be more than £8 million. Colonis expects to
steal market share as doctors have to prescribe
the licensed version of a drug, killing sales of nonlicenced
treatments.
Given the level of growth Quantum isn’t too
expensive at 111.5p. A 7.4p prospective basic
earnings per share (EPS) puts the stock on 15
times earnings this year, falling to 13.9 times next
year on an 8p EPS.
Management do not rule out acquisitions to
bring new products or expertise into the business.
ShareS SayS:
Momentum is building and with new products
and contracts expected Quantum is set to
report strong profit growth in the coming years.